On April 18, 2022 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that in vivo data showing PH-762 administered locally clears untreated distal tumors, indicating a systemic immune response was selected for an encore presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Tumor Immune Microenvironment: A Holistic Approach Workshop, which is being held April 21st – 22nd in San Diego and virtually (Press release, Phio Pharmaceuticals, APR 18, 2022, View Source [SID1234612403]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details are as follows:
Title: Locally administered immunotherapy self-delivering RNAi PH-762 results in abscopal clearance of untreated distal tumors, suggesting systemic immune response, in a murine hepatocarcinoma model
Presenter: Simon Fricker
Abstract Number: 019
Session Date and Time: April 21st from 5:20 p.m. – 6:20 p.m. PT
Location: Sheraton San Diego Hotel and Marina in San Diego

The poster will be made available on the "Investors – Events and Presentations" section of the Company’s website (click here).